radiomics.bio Announces New Chairman

Jan Groen has over twenty-five years of experience in the clinical precision diagnostics and biotech industry, which provides critical market insight as radiomics.bio drives forward its commercial pharma service roll-out. He is also a recognized expert in biomarker discovery, cancer genetics and molecular diagnostics having earned multiple awards, holding several patents and having published over 125 scientific publications. Furthermore, Jan has vast experience in guiding successful life science ventures by increasing shareholder value and helping EU companies expand into the US market. 

"We are incredibly grateful for the contributions Michel has made within the company over the last few years, especially during pivotal moments in the company's development. We wish him the best in his new endeavors,”stated Wim Vos, Chief Executive Officer of radiomics.bio. “Also, we are pleased to have Jan on board who brings undeniable experience with the specific knowledge that will truly allow us as a company to break barriers into other markets.”

“I am excited to lead the board and work with my fellow board members, between the expertise, knowledge and experience of not only the board but also internally on the radiomics.bio team, there is a great window of opportunity for us to expand into something great, building on what has already been achieved and make significant advancements in drug development,”stated Dr. Jan Groen. 

“We have seen quite a few changes in the company’s structure as of late, we are looking forward to seeing the fruits that it will produce, our gratitude remains with those both past and present that have allowed radiomics.bio to solidify its position in the optimization of drug development and will allow the company to continue to flourish,”stated Leen Limbourg MD, representative of Noshaq Group, radiomics.bio’s primary investor. 

About radiomics.bio: 

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization, optimizing the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information visit www.radiomics.bio.

Contact info: 

radiomics.bio 

Wim Vos, CEO 

E: [email protected] 

T: +32 4 295 73 94